In particular, HER2 signaling is known to upregulate LDH‐A and HIF1α expression (Zhao et al., 2009), while HER2 downregulation or pharmacologic inhibition with trastuzumab reverses the glucose dependency and inhibits glycolytic metabolism in HER2‐positive BC cells (Walsh et al., 2013). The gene discussed is ERBB2; the disease is breast cancer.